Identification of midkine as a mediator for intercellular transfer of drug resistance

Bernard L Mirkin1, Sandra Clark, Xin Zheng

  • 1Children's Memorial Research Center (CMRC), Cancer Biology Program, Chicago, IL 60614, USA.

Oncogene
|May 18, 2005
PubMed

Insights

Drug-resistant cancer cells protect sensitive neighbors via secreted midkine, a survival molecule. This intercellular signaling, involving the Akt pathway, contributes to chemotherapy resistance by preventing apoptosis and proliferation arrest.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Chemotherapy resistance is a major obstacle in cancer treatment.
  • Mechanisms include drug efflux, altered drug targets, and apoptosis evasion.
  • Existing resistance mechanisms don't fully explain co-survival of sensitive and resistant cells.

Purpose of the Study:

  • To investigate the hypothesis of a cytoprotective relationship between drug-resistant and drug-sensitive cancer cells.
  • To identify secreted factors from resistant cells that protect sensitive cells.
  • To elucidate the role of midkine in mediating this protective effect.

Main Methods:

  • cDNA array analysis to identify differentially expressed genes in resistant cells.
  • Affinity chromatography to isolate midkine-enriched fractions.
  • Treatment of drug-sensitive cells with midkine fractions and doxorubicin.
  • Gene transfection of sensitive cells with midkine.
  • Analysis of the Akt pathway and cell death markers.

Main Results:

  • Midkine was identified as exclusively expressed in drug-resistant cells.
  • Midkine fractions significantly protected drug-sensitive cells from doxorubicin toxicity.
  • Midkine gene transfection decreased doxorubicin sensitivity in wild-type cells.
  • Midkine-mediated protection involved Akt pathway activation and inhibition of apoptosis and proliferation arrest.

Conclusions:

  • Drug-resistant cancer cells secrete midkine, providing a cytoprotective signal to neighboring sensitive cells.
  • Midkine contributes to the development of chemotherapy resistance through intercellular communication.
  • Targeting midkine-mediated signaling may offer novel therapeutic strategies against chemoresistance.

Related Concept Videos

Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Cellular Membranes and Drug Transport01:24

Cellular Membranes and Drug Transport

Drugs must traverse multiple biological barriers, such as multi-layered skin, single-layered intestinal epithelium, and the plasma membrane, to reach their target sites within the body. The plasma membrane, a highly structured composite of phospholipids, carbohydrates, and proteins, is the cell's protective boundary, facilitating selective substance exchange.
Phospholipids arrange themselves into a bilayer, with hydrophilic heads oriented outward and hydrophobic tails facing inward.
Pore Transport and Ion-Pair Transport01:17

Pore Transport and Ion-Pair Transport

Pore transport and ion-pair formation are critical mechanisms for the absorption and distribution of drugs in the body.
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited  but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct microscopic...
Mechanisms of Drug Absorption: Paracellular, Transcellular, and Vesicular Transport01:23

Mechanisms of Drug Absorption: Paracellular, Transcellular, and Vesicular Transport

Drugs need to permeate cell membranes to reach their target sites after administration. Orally administered drugs must transcend intestinal epithelial membrane barriers to infiltrate the systemic circulation. Drugs with a molecular weight of less than 500 Daltons diffuse through gaps between neighboring cells, called paracellular pathways.
However, most drugs use the transcellular route, traversing directly through the cell membranes via two mechanisms: passive and active transport. Passive...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...